Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2024

  1. Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia

  2. Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease

    Journal of Clinical Medicine, Vol. 13, Núm. 3

  3. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 721-726

  4. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

  3. Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress

    Frontiers in immunology, Vol. 14, pp. 1185517

  4. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  5. Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 109-115

  6. Randomized clinical trial evaluating three low-volume preparations for colonoscopy in outpatients with Inflammatory Bowel Disease: the EII-PREP trial

    Scandinavian Journal of Gastroenterology, Vol. 58, Núm. 6, pp. 656-663

  7. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. A first update on mapping the human genetic architecture of COVID-19

    Nature

  2. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  3. Metabolomics study of COVID-19 patients in four different clinical stages

    Scientific reports, Vol. 12, Núm. 1, pp. 1650

  4. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  5. Whole-genome sequencing reveals host factors underlying critical COVID-19

    Nature, Vol. 607, Núm. 7917, pp. 97-103

2021

  1. Doppler Activity and Ultrasonographic Detection of Intra-Abdominal Fistulas Are Predictors of Surgery in Crohn's Disease

    Digestive Diseases, Vol. 39, Núm. 3, pp. 204-210

  2. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  3. Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract

    Molecular Nutrition and Food Research, Vol. 65, Núm. 12

  4. Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates between Type and Mucosal Status in Patients with Inflammatory Bowel Disease

    Inflammatory Bowel Diseases, Vol. 27, Núm. 2, pp. 268-274